Case of Pediatric Bullous Systemic Lupus Erythematosus Treated with Intravenous Immunoglobulin. Issue 1 (25th October 2016)

• Record Type: Journal Article
• Authors: Juhász, Margit; Rogge, Megan; Chen, Mary; Czernik, Annette; Jung Kim, Soo; Geller, Lauren
• Is Part Of: Pediatric dermatology. Volume 34:Issue 1(2017:Jan./Feb.)
• Page Start: e54
• Page End: e56
• Publication Date: 2016-10-25
• Subjects: Pediatric dermatology -- Periodicals; Children -- Diseases -- Periodicals; 618.925
• DOI: 10.1111/pde.13015
• Languages: English
• ISSNs: 0736-8046

Abstract

Abstract: This is a case report of a 16‐year‐old girl recently diagnosed with systemic lupus erythematosus (SLE) who presented with multiple blisters on the face, hands, arms, legs, trunk, and vaginal and oral mucosa. Skin biopsy was consistent with bullous SLE (BSLE). Dapsone is often the first‐line treatment option for BSLE, but the patient's history of anemia and leukopenia and long‐term immunosuppression requirement for her systemic symptoms raised concerns about dapsone and bone marrow toxicity, especially hemolytic anemia and agranulocytosis. She was started on intravenous immunoglobulin (IVIG), 2 g/kg divided over 3 days, with significant improvement in her cutaneous symptoms. IVIG is a treatment option for BSLE patients in whom agents such as dapsone are contraindicated.